Fujitsu和Tokai国家体系利用AI加快日本临床试验的病人选择,目的是改善药物的获取。 Fujitsu and Tokai National System use AI to speed up patient selection for clinical trials in Japan, aiming to improve drug access.

Fujitsu和Tokai国家高等教育和研究系统已完成实地试验,使用AI处理临床数据,以选择日本临床试验参与者。 Fujitsu and Tokai National Higher Education and Research System have completed field trials using AI to process clinical data for selecting clinical trial participants in Japan. 目的是解决“毒品损失”问题,因为由于严格的审批程序,海外药品无法在当地提供。 This aims to address the issue of 'drug loss,' where drugs available overseas are not locally available due to strict approval processes. 这些试验利用了大约1 800个病人记录的数据,在数据结构安排方面实现了90%的准确性,加快了病人的选择,改善了临床试验的获得。 The trials, using data from about 1,800 patient records, achieved 90% accuracy in structuring data, speeding up patient selection and improving access to clinical trials. 今后的计划包括扩大范围并提高准确性,纳入临床试验平台,以加强数据使用和协作。 Future plans include expanding the scope and improving accuracy, with integration into clinical trial platforms to enhance data use and collaboration.